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Abstract

Molecular Modeling of Potential Inhibitors

Inhibitor Candidates

Fungal Growth Assay

Fungal infections occur when fungus invades the tissue, which can grow and
affect the whole body if left untreated. These infections are difficult to treat as
there are few drugs on the market that can target fungi and they have serious
and harmful side effects towards the patient. In an effort to stop fungal
infections, we are developing a new method of inhibition. An enzyme critical
for life, methionine synthase, has a key difference between fungi and humans
that can be exploited. An inhibitory molecule can be made to selectively target
fungal methionine synthase based on this difference. Utilizing Autodock, a
modelling software, molecular modelling was done to develop theoretical
molecules that target the fungal enzyme. Based on the theoretical modelling, a
library of potential inhibitors was synthesized. The potential inhibitors were
tested in an assay measuring the activity of the fungal enzyme in the presence
of our inhibitors. The molecules are further tested in a fungal growth assay
which show zones of inhibition that would prove our molecules are active.

Using the modeling program AutoDock, we can virtually screen potential
molecules to confirm they can reach both binding sites (Fig. 5).3

By using methods similar to those shown in Figures 7 and 8, a number of
similar potential inhibitors have been synthesized (Fig. 9). This library of
molecules provides a number of subtle structural differences. The hope is that
these small changes will help identify a molecule that has the perfect “fit” in
the enzyme.

Another way we tested our inhibitors was through a fungal growth assay,
referred to as a Kirby-Bauer test. Discs containing our compounds are exposed
to various microorganisms. Successful inhibitors will prevent fungal and
bacterial growth, which can be shown by zones of inhibition on the plates.

Background

Figure 5: The four molecules above give a representation of
four good inhibitors, binding in the folate and Hcy pockets

Fungal infections are a common public health concern especially in regards to
immunocompromised patients who are at a greater risk of death in such cases.1
As there is an increase of drug resistant fungi, there is a need for new types of
antifungal drugs. Methionine Synthase (MetSyn), an enzyme which converts
homocysteine (Hcy) to methionine using a substituted folate molecule (Fig. 1),
could provide a potential pathway for safe antifungal treatment.

Figure 1: Net reaction of MetSyn

The structure of MetSyn used by fungi
is different than that used by
mammals.2 In the fungal enzyme,
folate and homocysteine bind to two
pockets that are close together (Fig. 2).
In humans, the folate and Hcy binding
pockets are very far apart. This makes
it possible to design synthetic
compounds which could bind the
folate and homocysteine pockets at the
same time in the fungal enzyme, while
being unable to competitively bind the
mammalian MetSyn form (Fig. 3).

Figure 6: Inhibitor H is a prime example of a good inhibitor as
it binds in open conformation (left) and fits in the closed
conformation (right) of MetSyn

When modeling the
potential inhibitors,
we look to see that
our folate mimic is in
the folate binding
pocket and that our
amino acid tail is in
the HCy binding
pocket. These results
confirm that a single
molecule
can
simultaneously bind
both pockets within
the fungal enzyme.
MetSyn can exist in two
conformations: open and
close. It conforms to the
closed upon substrates
binding.
A
good
inhibitor should bind to
the open enzyme while
still being able to fit in
the closed conformation,
such as that shown in
Figure 6.

Representative Inhibitor Syntheses
Figure 7 represents the synthesis of one of our compounds (inhibitor U). Many of
our inhibitors follow similar synthetic steps, putting together a folate mimic, linker,
and amino acid tail.

Figure 2: In fungal MetSyn, folate
and Hcy bind in close proximity.

Therefore, compounds designed to
inhibit fungal MetSyn could serve as
antifungal drugs which should not
affect the biochemistry of the patient.

A molecule specific for fungal MetSyn would need a folate mimic attached to
a Hcy mimic by some short linker (Fig. 4). This should properly fit in the
fungal enzyme, because the two binding pockets are so close together.
A molecule outlined from Figure 4
would work as a competitive
inhibitor. The folate mimic would
bind and block natural folate, and
the homocysteine mimic would
prevent the natural homocysteine
Figure 4: Generalized Inhibitor Molecule
from binding.
A molecule such as this would not be expected to interfere with the
mammalian MetSyn enzyme, as it would lack the ability to span both
binding pockets, resulting in non-specific binding.

Testing inhibitors via Enzyme Assay
To test whether our inhibitors can effectively inhibit fungal methionine synthase, a
fluorescence assay is used.5 A fluorescent reagent is added, and the fluorescence
correlates to Hcy concentration. This allows us to track the activity of the enzyme
indirectly with the concentration of Hcy (Fig. 10).
The first set of triplicates are
blanks, followed by a triplicate of
the positive control which contains
Hcy and fluoresces the most. Third
is the enzyme reaction, which
consumes HCy and lowers the
fluorescence. The last
five
triplicates are the various inhibitors
tested in that trial, with varying
amounts of inhibition. High
fluorescence means successful
inhibition, as the enzyme can’t
consume Hcy to make methionine.
Figure 10: Well plate showing results from a fluorescence assay. High fluorescence
represents high Hcy concentration and low enzyme activity.

Figure 3: Cartoon model for a molecule
binding fungal MetSyn, but will not properly
fit inside human MetSyn.

General Design of Molecules

Figure 9: Current library of inhibitors that are being tested, all with slight variation but following
same general design.

Figure 12: Inhibitor activity against two strains of fungi Candida albicans (C.A) and
Saccharomyces cerevisiae (S.C), as well as two bacterial strains Bacillus cereus (B.C) and
Staphylococcus aureus (S.A).

Inhibitors such as H, P, N, S, and T show promise in the fungal growth assay,
which agree with the results of the fluorescence assay. When these results are
paired together, these molecules can successfully inhibit the methionine synthase
enzyme, and are able to stop the growth of various fungi and bacteria. From this
test, we can show that our inhibitors are successful in killing and stopping the
growth of various pathogenic organisms.

Conclusions and Future Directions
Using molecular modelling, potential inhibitor candidates were found and then
synthesized based on the best structures. The library of synthesized inhibitors
were tested in a fluorescence assay to determine activity against the fungal
enzyme. These compounds were then tested against various microorganisms in
the fungal growth assay. From these, we have developed a library of working
inhibitors that stop the growth of various microorganisms. Moving forward, the
mechanism for inhibiting the growth of the fungi can be tested in a modified
Kirby-Bauer test. More modelling can be done to develop more potential
inhibitors, and our library of inhibitors can be expanded on and tested further.
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Figure 11: Preliminary inhibitor screen; High Fluorescence correlates to low enzyme activity

Figure 8: Synthesis of a new inhibitor candidate currently under development

This assay identifies which inhibitors show the most promise. From these
results, inhibitors H and P appear most active, as the high fluorescence
indicates low production of methionine.
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